Analyst Issues Sell Rating for GlaxoSmithKline Amid Legal Challenges and Financial Risks
Barclays Remains a Hold on GlaxoSmithKline (GSK)
The latest pharmaceutical industry rating by S&P reveals that Johnson & Johnson (JNJ.US) and Roche (RHHBY.US) are ranked at the top for superior financial and innovative abilities.
Goldman Sachs Sticks to Its Hold Rating for GlaxoSmithKline (GSK)
Berenberg Bank Reaffirms Their Buy Rating on GlaxoSmithKline (GSK)
Berenberg Bank Keeps Their Buy Rating on GlaxoSmithKline (GSK)
Argus Research Remains a Buy on GlaxoSmithKline (GSK)
Citi Reaffirms Their Buy Rating on GlaxoSmithKline (GSK)
Kepler Capital Sticks to Its Hold Rating for GlaxoSmithKline (GSK)
Bank of America Securities Sticks to Their Sell Rating for GlaxoSmithKline (GSK)
Goldman Sachs Sticks to Its Hold Rating for GlaxoSmithKline (GSK)
Deutsche Bank Keeps Their Buy Rating on GlaxoSmithKline (GSK)
J.P. Morgan Keeps Their Sell Rating on GlaxoSmithKline (GSK)
GlaxoSmithKline Sell Rating Justified by Arexvy Underperformance and Reduced Revenue Projections
GlaxoSmithKline (GSK) Receives a Buy From Jefferies
GlaxoSmithKline (GSK) Receives a Buy From Deutsche Numis
Buy Rating for GlaxoSmithKline Backed by Sales Trends and Strong Revenue Growth Potential
Citi Sticks to Their Buy Rating for GlaxoSmithKline (GSK)
UBS Sticks to Its Buy Rating for GlaxoSmithKline (GSK)
J.P. Morgan Keeps Their Sell Rating on GlaxoSmithKline (GSK)
No Data